RCUS Q3 2023 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M-3.0% YoY

Gross Profit

$32M100.0% margin

Operating Income

-$80M-250.0% margin

Net Income

-$71M-221.9% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

+10.3%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$73M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$671M

Stockholders' Equity

$520M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$33M	-3.0%
Gross Profit	$32M	$33M	-3.0%
Operating Income	-$80M	-$70M	-14.3%
Net Income	-$71M	-$65M	-9.2%

Revenue Segments

License and Development Services Revenue

$22M69%

Other Collaboration Revenue

$10M31%